AbCellera Biologics (ABCL) Gross Profit: 2019-2024
Historic Gross Profit for AbCellera Biologics (ABCL) over the last 6 years, with Dec 2024 value amounting to $16.1 million.
- AbCellera Biologics' Gross Profit fell 69.62% to $6.1 million in Q4 2023 from the same period last year, while for Dec 2023 it was $23.8 million, marking a year-over-year decrease of 94.31%. This contributed to the annual value of $16.1 million for FY2024, which is 32.67% down from last year.
- According to the latest figures from FY2024, AbCellera Biologics' Gross Profit is $16.1 million, which was down 32.67% from $23.8 million recorded in FY2023.
- Over the past 5 years, AbCellera Biologics' Gross Profit peaked at $419.0 million during FY2022, and registered a low of $16.1 million during FY2024.
- Over the past 3 years, AbCellera Biologics' median Gross Profit value was $23.8 million (recorded in 2023), while the average stood at $153.0 million.
- Per our database at Business Quant, AbCellera Biologics' Gross Profit soared by 1,890.65% in 2020 and then crashed by 94.31% in 2023.
- Yearly analysis of 5 years shows AbCellera Biologics' Gross Profit stood at $206.0 million in 2020, then skyrocketed by 60.03% to $329.7 million in 2021, then grew by 27.09% to $419.0 million in 2022, then plummeted by 94.31% to $23.8 million in 2023, then plummeted by 32.67% to $16.1 million in 2024.